UK – NICE u-turn sees Akcea’s Waylivra win NHS funding

FCS is the name for a group of rare genetic disorders that affect between 55 and 110 people in England. The condition results in very high levels of triglycerides in the blood, causing symptoms such as repetitive episodes of severe abdominal pain, unpredictable and recurrent episodes of acute pancreatitis, enlargement of the liver and spleen and fatigue.

Waylivra, a product of Ionis’ proprietary antisense technology, is designed to reduce the production of ApoC-III, a protein that regulates plasma triglycerides and may also affect other metabolic parameters…